ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Clinical Features, Molecular Biology, and the Metastatic Microenvironment in Lung Cancer Brain Metastases: Implications for Treatment Decisions.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Lung Cancer Brain Metastasis: Brain Microenvironmental Adaptation, Therapeutic Resistance and Translational Strategies.Cancer science · 2026Review
- Association Between Treatment Sequencing and Overall Survival in Stage IV NSCLC With Brain Metastases: A National Cancer Database Study.Thoracic cancer · 2026Article
- Exploring the effectiveness and sequence of brain local treatment combined with thoracic surgery in non-small cell lung cancer patients with brain oligometastasis.Translational lung cancer research · 2026Article
- Systemic inflammatory indices as accessible biomarkers for intracranial outcome and prognosis in driver gene-negative NSCLC with brain metastases treated with first-line chemoimmunotherapy.Discover oncology · 2026Article
- Metal-Organic Framework Nanozymes: From Rational Design and Synthesis to Biomedical Applications.Nano-micro letters · 2026Review
- Association of regional specificity of blood-brain barrier permeability with pathological subtypes in cerebral white matter of patients with non-brain metastatic lung cancer.Frontiers in oncology · 2026Article
- Clinical Features, Molecular Biology, and the Metastatic Microenvironment in Lung Cancer Brain Metastases: Implications for Treatment Decisions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Pan-immune-inflammation value as an independent prognostic marker in patients with brain metastases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Brain metastases (BM) represent a highly aggressive, clinically distinct subtype of lung cancer, often associated with poor prognosis. Historically, treatment options for BM have been limited and largely nonspecific. However, recent advancements in clinical and preclinical research have led to substantial improvements in patient outcomes. This review focuses on BM arising from lung cancer, providing an overview of recent findings related to clinical characteristics, diagnostic strategies, and early metastatic processes. Multi-omics analyses have elucidated the molecular mechanisms underlying tumor initiation and progression, with particular emphasis on the role of the tumor microenvironment. In this review, preclinical BM models, detailed signaling pathways, and emerging clinical therapies are also discussed. Current treatment approaches are multidisciplinary, and multi-omics technologies enhance both diagnosis and therapeutic strategies by revealing the complex biology of BM. Continued research is needed to identify BM-specific drug targets, particularly those involved in crossing the blood-brain barrier and remodeling the brain microenvironment. Addressing these challenges is crucial for improving clinical outcomes in patients with BM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.